0001788028 2026-07-16 2026-07-16 0001788028 JSPR:VotingCommonStockParValue0.0001PerShareMember 2026-07-16 2026-07-16 true 0001788028 8-K/A 2026-07-16 JASPER THERAPEUTICS, INC. DE 001-39138 84-2984849 2200 Bridge Pkwy Suite #102 Redwood City CA 94065 650 549-1400 false false false false Voting Common Stock, par value $0.0001 per share JSPR NASDAQ false On July 16, 2026, Jasper Therapeutics, Inc. (the “Company” or “Jasper”) filed a Current Report on Form 8-K (the “Original Form 8-K”) reporting that, on the same date, the Company completed its acquisition (the “Merger”) of Kira Pharmaceuticals (“Kira”), a Cayman Islands exempted company, pursuant to the terms of the Agreement and Plan of Merger, dated July 16, 2026 (the “Merger Agreement”), by and among the Company, Kira Holdco Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”), and Kira. Pursuant to the Merger Agreement, Kira merged with and into Merger Sub, with Merger Sub continuing as the surviving corporation and a wholly owned subsidiary of the Company. This Current Report on Form 8-K/A amends Item 9.01 of the Original Form 8-K to include the financial statements and unaudited pro forma financial information required by Items 9.01(a) and (b) of Form 8-K, which were not included in the Original Form 8-K pursuant to Items 9.01(a)(3) and (b)(2) of Form 8-K.